Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)

Critical Illness Clinical Trial

Official title:

Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00316576
• Other study ID #: 05-130
• Status: Terminated
• Phase: N/A
• First received: April 19, 2006
• Last updated: January 16, 2008
• Start date: May 2006
• Est. completion date: November 2006

Study information

• Verified date: January 2008
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Description:

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 160
• Est. completion date: November 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 yrs

• ICU stay > 48 hours

Exclusion Criteria:

• Age < 18 yrs

• Creatinine > 180 µmol/L

• Absence of consent

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Kidney Injury
• Critical Illness
• Kidney Failure, Acute
• Renal Insufficiency

Intervention

Procedure:
• Blood sampling for PCR

Locations

Country	Name	City	State
France	Medical Intensive care Unit; Caen University Hospital	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of ARF		During ICU stay	Yes
Secondary	Mortality		ICU and Hospital mortality	Yes